MARKET

XOMA

XOMA

Xoma Corp Del
NASDAQ
24.59
+0.34
+1.40%
Closed 16:02 04/18 EDT
OPEN
24.25
PREV CLOSE
24.25
HIGH
25.06
LOW
24.24
VOLUME
14.87K
TURNOVER
0
52 WEEK HIGH
27.00
52 WEEK LOW
13.48
MARKET CAP
286.11M
P/E (TTM)
-6.0919
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at XOMA last week (0408-0412)?
Weekly Report · 4d ago
Weekly Report: what happened at XOMA last week (0401-0405)?
Weekly Report · 04/08 11:45
*News On Kinnate Biopharma Inc. (KNTE) Now Under XOMA
Dow Jones · 04/03 21:08
XOMA CORPORATION ANNOUNCES CLOSING OF TENDER OFFER
Reuters · 04/03 13:00
Press Release: XOMA Corporation Announces Closing of Tender Offer
XOMA Corporation Announces Closing of Tender Offer Kinnate Stockholders to Receive $2.5879 Per Share in Cash Plus Contingent Value Right. XOMA has successfully completed its previously announced tender offer to acquire all outstanding shares of Kinnate Biopharma Inc. Kinnate stockholders will receive a price per share of $2,5879 in cash plus one non-tradeable contingent value right.
Dow Jones · 04/03 13:00
Weekly Report: what happened at XOMA last week (0325-0329)?
Weekly Report · 04/01 11:42
Weekly Report: what happened at XOMA last week (0318-0322)?
Weekly Report · 03/25 11:45
Press Release: XOMA Declares Quarterly Preferred Stock Dividends
XOMA Corporation is a biotechnology royalty aggregator. The preferred dividends will be paid on or about April 15, 2024. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates. The Company has an extensive and growing portfolio of assets.
Dow Jones · 03/21 11:30
More
About XOMA
XOMA Corporation is a biotechnology royalty aggregator. The Company’s royalty aggregator business is primarily focused on early to mid-stage clinical assets, primarily in Phase I and II, with significant commercial sales potential that are licensed to larger pharmaceutical partners. The Company has a portfolio of economic rights and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. Its royalty portfolio includes DAY101 (tovorafenib), JNJ-63723283 (cetrelimab), RZ358, arimoclomol, TAK-079 (mezagitamab), BAY-1213790 (osocimab), AFM13 (acimtamig), AB023 (gruticibart), AB002 (E-WE thrombin), AB054, AV-299 (ficlatuzumab), COM902, vosaroxin, aldoxorubicin, INCAGN2385, INCAGN02390, MNPR-101, PBF-680, PBF-677, PBF-999, PBF-1129, PBF-1650, G03-52-01, RZ402, DSUVIA (sufentanil sublingual tablet), IXINITY [coagulation factor IX (recombinant)], VABYSMO (faricimab-svoa), CMP-001 (vidutolimod), and CFZ533 (iscalimab).

Webull offers XOMA Corp stock information, including NASDAQ: XOMA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, XOMA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading XOMA stock methods without spending real money on the virtual paper trading platform.